Association Between Knowledge of Hypoglycemia and Likelihood of Experiencing Hypoglycemia Among Patients with Insulin-Treated Diabetes Mellitus

Turky H Almigbal ^{1–3}

¹Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia; ²King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia; ³Vision College of Medicine, Vision Colleges in Riyadh, Riyadh, Saudi Arabia

Purpose: This study aimed to evaluate the association between a patient's knowledge about hypoglycemia and the likelihood of experiencing hypoglycemia.

Participants and Methods: This cross-sectional study used a structured questionnaire to survey a representative sample of 429 adult males with insulin-treated diabetes mellitus (ITDM) in Saudi Arabia.

Results: The main factors associated with increased risk of hypoglycemia included (a) a premixed insulin regimen, (b) a long duration of insulin treatment, (c) the use of oral hypoglycemic agents, and (d) a high hypoglycemia knowledge score. Insulin as a treatment modality directly affects the development of hypoglycemia among ITDM patients. Sweating is the most prevalent clinical manifestation among ITDM patients with hypoglycemia and could be an early indicator of hypoglycemia. Earlier detection of hypoglycemic signs may ultimately improve quality of life in ITDM patients.

Conclusion: This research highlights the importance of healthcare providers educating ITDM patients about hypoglycemia. Furthermore, our results emphasize the urgent need to establish an educational program about hypoglycemia. ITDM patients are encouraged to learn more about hypoglycemia to help prevent future hypoglycemic attacks.

Keywords: diabetes mellitus, insulin, hypoglycemia, hypoglycemia symptoms, patient education

Introduction

Diabetes mellitus (DM) is one of the most prevalent chronic diseases worldwide.¹ The global prevalence of DM is increasing and expected to rise from 463 million in 2019 to 578 million cases by 2030. In the Middle East, the prevalence of DM is expected to rise from 54.8 million cases in 2019 to 76.0 million in 2030. In Saudi Arabia, DM represents a major public health problem; 4.27 million cases were documented in 2019, which is projected to reach 6.05 million by 2030.^{2–5}

Individuals diagnosed with DM are at greater risk for mortality and morbidity due to diabetic complications, including macrovascular, microvascular, or acute complications. Common macrovascular complications among diabetics include heart failure, peripheral artery disease, and coronary heart disease.⁶ Microvascular complications include end-stage renal disease (ESRD), neuropathy, and diabetic retinopathy, which is a leading cause of blindness worldwide.⁷ The acute

Correspondence: Turkey H Almigbal
Email almogbal@yahoo.com

Received: 6 July 2021
Accepted: 20 August 2021
Published: 4 September 2021

complications of DM, which include diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), and hypoglycemia, are largely preventable, yet lead to high morbidity and mortality. Although the global status of diabetes complication rates remains unclear,⁸ mortalities due to DM are estimated to contribute to 11.3% of deaths globally, with the highest rate recorded in the Middle East and North Africa (16.2%).⁹

Hypoglycemia is the most common iatrogenic acute metabolic complication among diabetics,^{10–12} and it is defined as serum glucose levels <70 mg/dL (3.9 mmol/L), which is mainly encountered by patients on insulin treatment as a result of its hypoglycemic effects.¹³ Although avoidable, hypoglycemia was the primary cause for the elevated number (300,000) of adult emergency department visits in the United States in 2009.¹⁴ In Saudi Arabia, the rate of acute complications due to hypoglycemic attacks was found to be high at 68.9% among patients with DM.¹⁵ Complications due to hypoglycemia can be serious and life threatening, including such as cardiac arrhythmia, cognitive impairment, and cerebral ischemia.¹⁶

The incidence of hypoglycemia among patients with DM is high,¹⁷ and poor hypoglycemia awareness can render diabetics prone to severe hypoglycemia.¹⁸ It is important to identify the association between hypoglycemia and related factors, such as the patient's hypoglycemia experience, awareness of glycemic control, and hypoglycemia itself. This information may help minimize or even eliminate the potential harm to patients with DM receiving insulin treatment.

Studies have shown that adequate knowledge about hypoglycemia is needed to recognize, treat, and prevent hypoglycemia,¹⁹ yet patients with DM have a gap in their knowledge on important aspects of hypoglycemia.²⁰ Improved hypoglycemia knowledge in diabetic patients led to a decrease in hypoglycemic episodes.²¹ In Saudi Arabia, research has shown that approximately 50% of patients with DM have a lack of knowledge about hypoglycemia symptoms; the authors concluded that health education about hypoglycemia symptoms is necessary for these patients.²²

Our study focuses on the association between diabetic patients' knowledge about hypoglycemia and their likelihood of experiencing a hypoglycemic episode. Furthermore, we studied the association between various sociodemographic and clinical variables and hypoglycemia among patients with insulin-treated diabetes mellitus (ITDM) in Saudi Arabia.

Methods

Study Design and Settings

This research project was part of the Diabetes and Driving (DAD) study, which was a cross-sectional study conducted among ITDM participants in which data were collected from two specialized diabetes clinics affiliated with tertiary hospitals in Riyadh, Saudi Arabia. The detailed methodology of the DAD study was previously published and will be briefly described here.²³

Participant Enrollment

The participants of the DAD study consisted of adult men (age >18) with ITDM who were followed up for a minimum of 1 year in the diabetes clinic.²³ The data were collected by interviewing participants who met the eligibility criteria and who consented to participating after they had completed their clinic consultations; the study's objectives were explained, and written consent was obtained. Four data-collection-experienced medical students collected the data at random 4-h intervals every other day over a seven-month period extending from August 2016 to February 2017. The four students who collected the data were informed of the study's objectives, and the questionnaire was explained to them by the principal investigator; these four students also participated in the pilot study.

Study Instrument

The interview questionnaire was developed following an extensive literature review and is based on available international guidelines; the process is discussed in detail in the original study.²³ The questionnaire was initially developed in English and was then translated to Arabic and back-translated to English by two accredited translators. The final Arabic version was piloted among 20 participants from general medicine clinics. The questionnaire's reliability was tested using the test-retest method, yielding a correlation coefficient >0.7 for all items.

Study Sample

The required calculated sample size was 399 based on the results of the pilot study. Due to a 20% non-response rate in the pilot study, the final sample size required was 499 participants.²³

Statistical Analysis

Descriptive statistics were used to analyze the collected data in the form of frequency values. Multivariable logistic

regression analyses were performed to identify factors that may increase the risk of hypoglycemia among participants with ITDM. The study results were considered statistically significant when $P < 0.05$. The Kolmogorov–Smirnov test was used to determine the normality of the data. All data were analyzed using SPSS Statistics V22.0 (IBM Corp., Armonk, NY, USA).^{24,25}

Ethical Considerations

The institutional review board at King Saud University Medical City (Saudi Arabia, Riyadh) granted ethical approval of the original study's protocol (Ref. No. 16/0227/IRB). This study was conducted in accordance with the Declaration of Helsinki.

Results

The questionnaire had a response rate of 89.3%; 429 of the 480 initially approached ITDM patients agreed and consented to be interviewed and to participate in the study. More than half of the sample (59.7%) had ITDM for ≥ 15 years, and approximately half of the sample (51.3%) had used insulin for ≥ 5 years. Additional sociodemographic variables are listed in Table 1. Knowledge of hypoglycemic symptoms among ITDM patients varied widely (Table 2). The most recognized hypoglycemia symptoms were tremor (90.68%), hunger (85.78%), and sweating (85.31%). Knowledge of tremor and hunger symptoms did not differ significantly between ITDM patients who did and did not experience hypoglycemia. In contrast, sweating was the most recognized symptom among ITDM patients, and the number of ITDM patients who experienced hypoglycemia who were knowledgeable about sweating ($n = 255$) was approximately twice that of ITDM patients who did not experience hypoglycemia ($n = 111$). In addition to sweating, ITDM patients who experienced hypoglycemia were more knowledgeable, relative to those who did not experience hypoglycemia, about the symptoms of cognitive impairment (49.14% vs 29.71%; $P < 0.001$), behavioral changes (43.99% vs 22.46%; $P = 0.001$), psychomotor abnormalities (35.05% vs 15.22%; $P < 0.001$), and coma (34.36% vs 22.46%; $P = 0.012$).

Experiencing hypoglycemia was associated with various sociodemographic characteristics. Type of DM, insulin regimen, insulin total daily dose, duration of insulin treatment, use of oral hypoglycemics, and hypoglycemia knowledge score all showed a statistically significant

Table 1 Sociodemographic Data for the Study Sample ($N = 429$)

Participant Sociodemographics		n ^a (%)
Age (years)	≤ 60	323 (75.3)
	> 60	106 (24.7)
Highest education level	No school attended	16 (3.7)
	Primary school attended	61 (14.3)
	Secondary school attended	57 (13.3)
	Tertiary school attended	134 (31.2)
	University or college	130 (30.4)
	Master or PhD	31 (7.2)
Location	Riyadh	409 (95.3)
	Outside Riyadh	20 (4.7)
Current occupation	Unemployed	54 (12.6)
	Private work	65 (15.2)
	Governmental work	142 (33.1)
	Retired	168 (39.2)
Monthly income	< 5000 SR ^b	150 (35)
	5000–10,000 SR	135 (31.5)
	10,001–15,000 SR	87 (20.3)
	$> 15,000$ SR	57 (13.3)
Type of diabetes	Type 1	112 (26.1)
	Type 2	317 (73.9)
Duration of diabetes (years)	≤ 15	256 (59.7)
	> 15	173 (40.3)
Insulin regimen	Basal only	93 (21.7)
	Pre-mixed insulin	189 (44.1)
	Basal/boluses	147 (34.2)
Total daily dose of insulin (U)	≤ 62	234 (54.5)
	> 62	195 (45.5)
Duration of insulin treatment (years)	≤ 5	220 (51.3)
	> 5	209 (48.7)
Use of Sulphonylurea or Glinides	Yes	110 (25.6)
	No	319 (74.4)

Notes: ^aNumber; ^bSaudi riyal.

unadjusted association with experiencing hypoglycemia ($P < 0.05$). Further, 70.45% of ITDM patients who experienced hypoglycemia had type 2 DM, whereas only 29.55% had type 1 DM ($P = 0.018$). In addition to DM type, a higher duration of insulin treatment was associated with hypoglycemia, with a mean duration of 8.25 ± 7.02 years ($P < 0.001$). Regarding the insulin treatment regimen, hypoglycemia was more prevalent among participants using premixed insulin compared to other insulin regimens (46.74%) of a basal/boluses insulin regimen (35.74%; $P = 0.002$). Higher hypoglycemia knowledge scores were associated with experiencing hypoglycemia

Table 2 Hypoglycemia Symptoms Among Patients Who Did and Did Not Experience Hypoglycemia

Clinical Manifestation	Hypoglycemia	No Hypoglycemia	Total	P
	n ^a (%)	n ^a (%)	n ^a (%)	
Adrenergic symptoms				
Tremor	268 (92.10%)	121 (87.68%)	389 (90.68%)	0.142
Palpitations	214 (73.54%)	97 (70.29%)	311 (72.49%)	0.481
Anxiety/arousal	185 (63.57%)	94 (68.12%)	279 (65.03%)	0.357
Sweating	255 (87.63%)	111 (80.43%)	366 (85.31%)	0.049
Hunger	251 (86.25%)	117 (84.78%)	368 (85.78%)	0.683
Paresthesia	170 (58.42%)	73 (52.90%)	243 (56.64%)	0.281
Neuroglycopenic symptoms				
Cognitive impairment	143 (49.14%)	41 (29.71%)	184 (42.89%)	<0.001
Behavioral changes	128 (43.99%)	31 (22.46%)	159 (37.06%)	<0.001
Psychomotor abnormalities	102 (35.05%)	21 (15.22%)	123 (28.67%)	<0.001
Seizure	26(8.93%)	11(7.97%)	37(8.62%)	0.741
Coma	100 (34.36%)	31 (22.46%)	131 (30.54%)	0.012

(mean knowledge score: 6.33 ± 2.49 ; $P < 0.001$). No significant association was found between experiencing hypoglycemia and the remaining sociodemographic characteristics, as illustrated in Table 3. Regarding hypoglycemia, a higher knowledge score increased the likelihood of ITDM patients experiencing hypoglycemia by 15% relative to other patients [OR = 1.15 (1.049, 1.26); $P = 0.003$]. A longer duration of insulin treatment (in years) also increases the chance of experiencing hypoglycemia by 6% [OR = 1.06 (1.009, 1.11); $P = 0.021$]. ITDM patients who receive a higher total daily insulin dose are at 1% higher risk of experiencing hypoglycemia [OR = 1.01 (1.003, 1.02); $P = 0.004$; Table 4].

Regarding low hypoglycemia knowledge scores (≤ 6), ITDM patients who did not experience hypoglycemia were 52% more likely to have a lower knowledge score than those who experienced hypoglycemia (Table 5).

Discussion

The current study sought to evaluate the association between ITDM patients' knowledge of hypoglycemia and their likelihood of experiencing a hypoglycemic episode. Furthermore, this study identified sociodemographic characteristics that may be risk factors for hypoglycemia among adult ITDM patients within Saudi Arabia. Further research is warranted on the correlation between experiencing hypoglycemia in ITDM patients and additional sociodemographic factors, such as type of diabetes, duration of diabetes, duration of insulin treatment, and total daily insulin dose. Hypoglycemic symptoms fall into two main

categories: adrenergic symptoms are caused by rapid changes in glucose levels, while neuroglycopenic symptoms are caused by low levels of central nervous system glucose.²⁶ In their study, 87.63% of the ITDM patients who experienced hypoglycemia were found to report sweating as the most significant clinical symptom associated with hypoglycemic attack. In other studies,²⁷ sweating was the most commonly reported symptom among ITDM patients. In addition, nearly half of the sample's constituents who experienced hypoglycemia complained of cognitive impairment and behavioral changes at rates of 49% and approximately 44%, respectively. The high rate of sweating as a clinical symptom among ITDM patients who developed hypoglycemia suggests that sweating can be used as a warning sign to prevent the development of a severe hypoglycemic attack. Such an observation was reported in a scientific report, which found that sweating during hypoglycemia may be a noninvasive warning sign.¹⁸

We also found evidence for a direct relationship between experiencing hypoglycemia and multiple sociodemographic characteristics among ITDM patients including the DM type, duration of insulin treatment in years, total daily insulin doses, and a good hypoglycemia knowledge score. Based on the type of DM, patients with type 2 DM were twice as likely to experience hypoglycemia than type 1 DM patients. The duration of insulin treatment affects the likelihood of developing hypoglycemia; ITDM patients with more years of insulin treatment have a 6% higher chance of developing hypoglycemia

Table 3 Sociodemographic Characteristics Related to Experiencing Hypoglycemia in ITDM Patients

Sociodemographics	Hypoglycemia	No Hypoglycemia	Total	P
Age (Years)	48.59 ± 16.05	51.54 ± 13.06	49.54 ± 15.20	0.060
Education				0.766
No school	9 (3.09%)	7 (5.07%)	16 (3.73%)	
Primary school	42 (14.43%)	19 (13.77%)	61 (14.22%)	
Secondary school	41 (14.09%)	16 (11.59%)	57 (13.29%)	
Tertiary school	87 (29.90%)	47 (34.06%)	134 (31.24%)	
University or college	89 (30.58%)	41 (29.71%)	130 (30.30%)	
Master or PhD	23 (7.90%)	8 (5.80%)	31 (7.23%)	
Current Occupation				0.771
Unemployed	40 (13.75%)	14 (10.14%)	54 (12.59%)	
Governmental work	95 (32.65%)	47 (34.06%)	142 (33.10%)	
Private work	44 (15.12%)	21 (15.22%)	65 (15.15%)	
Retired	112 (38.49%)	56 (40.58%)	168 (39.16%)	
Monthly Income				0.722
<5000 SR	103 (35.40%)	47 (34.06%)	150 (34.97%)	
5000–10,000 SR	95 (32.65%)	40 (28.99%)	135 (31.47%)	
10,001–15,000 SR	55 (18.90%)	32 (23.19%)	87 (20.28%)	
>15,000 SR	38 (13.06%)	19 (13.77%)	57 (13.29%)	
Smoking Status				0.277
Never smoked	163 (56.01%)	81 (58.70%)	244 (56.88%)	
Current smoker	63 (21.65%)	35 (25.36%)	98 (22.84%)	
Former smoker	65 (22.34%)	22 (15.94%)	87 (20.28%)	
Marital status				0.171
Single	49 (16.84%)	13 (9.42%)	62 (14.45%)	
Married	235 (80.76%)	123 (89.13%)	358 (83.45%)	
Divorced	5 (1.72%)	1 (0.72%)	6 (1.40%)	
Widowed	2 (0.69%)	1 (0.72%)	3 (0.70%)	
Location by City				0.482
Riyadh	276 (94.85%)	133 (96.38%)	409 (95.34%)	
Outside Riyadh	15 (5.15%)	5 (3.62%)	20 (4.66%)	
Type of diabetes				0.018
Type 1	86 (29.55%)	26 (18.84%)	112 (26.11%)	
Type 2	205 (70.45%)	112 (81.16%)	317 (73.89%)	
Duration of diabetes (Years)	14.78 ± 8.73	13.46 ± 7.75	14.36 ± 8.44	0.131
Regimen of insulin				0.002
Basal only	48 (16.49%)	45 (32.61%)	93 (21.68%)	
Pre-mixed Insulin	136 (46.74%)	53 (38.41%)	189 (44.06%)	
Basal/Boluses	104 (35.74%)	40 (28.99%)	144 (33.57%)	
Insulin pump	3 (1.03%)	0 (0.00%)	3 (0.70%)	
Use of oral hypoglycemic	62 (21.31%)	48 (34.78%)	110 (25.64%)	0.003
Duration of insulin treatment (Years)	8.25 ± 7.02	5.47 ± 5.42	7.35 ± 6.67	<0.001
Insulin total daily dose	66.41 ± 32.40	52.47 ± 31.81	61.93 ± 32.83	<0.001
Glucose checking				0.105
Once or more than once daily	94 (32.30%)	34 (24.64%)	128 (29.84%)	
Not daily	197 (67.70%)	104 (75.36%)	301 (70.16%)	
Knowledge score	6.33 ± 2.49	5.42 ± 2.36	6.04 ± 2.49	<0.001

Table 4 Variables Predicting Hypoglycemia Experience Among ITDM Patients

		Response=Hypoglycemia	
Covariate	Level	OR (95% CI)	OR P
Age (Years)		0.99 (0.961, 1.01)	0.320
Knowledge Score		1.15 (1.049, 1.26)	0.003
Education	No school Primary school Secondary school Tertiary school University or college	0.65 (0.254, 1.66) 1.08 (0.592, 1.99) 1.23 (0.68, 2.21) 0.80 (0.518, 1.23) 1.05 (0.652, 1.68)	0.368 0.793 0.498 0.312 0.853
Current Occupation	Governmental work Private work Retired	0.84 (0.558, 1.27) 0.93 (0.58, 1.50) 1.04 (0.671, 1.60)	0.417 0.770 0.872
Monthly Income	10,001–15,000 SR 5000–10,000 SR >15,000 SR	0.90 (0.591, 1.38) 1.23 (0.841, 1.80) 0.89 (0.515, 1.53)	0.630 0.285 0.664
Smoking Status	Current smoker Former smoker	0.71(0.492, 1.03) 1.45(0.971, 2.16)	0.071 0.069
Type of diabetes Duration of diabetes (Years) Duration of insulin treatment (Years) Insulin total daily dose	Type I	1.02(0.697, 1.48) 1.00(0.963, 1.04) 1.06(1.009, 1.11) 1.01(1.003, 1.02)	0.928 0.964 0.021 0.004

Table 5 Variables Predicting Poor Knowledge Score (≤ 6) About Hypoglycemia Among ITDM Patients

		Response = Knowledge Score ≤ 6	
Covariate	Level	OR (95% CI)	OR P
Age (Years)		1.01 (0.985, 1.03)	0.469
Education	No school Primary school Secondary school Tertiary school University or college	0.72 (0.273, 1.90) 0.81 (0.462, 1.43) 0.97 (0.567, 1.67) 1.05 (0.698, 1.59) 1.57 (0.997, 2.47)	0.506 0.476 0.916 0.807 0.052
Current Occupation	Governmental work Private work Retired	0.79 (0.541, 1.15) 0.84 (0.54, 1.31) 1.01 (0.666, 1.53)	0.216 0.443 0.958
Monthly Income	10,001–15,000 SR 5000–10,000 SR >15,000 SR	0.86 (0.576, 1.30) 1.11 (0.782, 1.58) 0.70 (0.424, 1.16)	0.482 0.556 0.168
Smoking Status	Current smoker Former smoker	0.77 (0.547, 1.09) 0.96 (0.666, 1.37)	0.139 0.807
Experienced hypoglycemia	No	1.52 (1.202, 1.92)	<0.001
Type of diabetes Duration of diabetes (Years) Duration of insulin treatment (Years) Insulin total daily dose	Type I	0.78 (0.554, 1.09) 1.00 (0.961, 1.03) 1.01 (0.962, 1.05) 1.00 (0.989, 1.00)	0.141 0.856 0.803 0.178

compared to those with fewer years of insulin use. A similar finding was described in a study that found a positive correlation between the NPH insulin among ITDM patients and nocturnal hypoglycemia.²⁸ Despite the low magnitude of the odds ratio between the duration of insulin treatment and the development of hypoglycemia, there is nevertheless a positive and statistically significant relationship. While the total insulin daily dose showed an association with hypoglycemia, it was to a lesser degree, as the ITDM patients receiving higher doses of daily insulin were only 1% more prone to hypoglycemia. ITDM patients were expected to develop more comprehensive knowledge about hypoglycemia, diabetes control, and self-care with a longer course of treatment; however, the converse was found to be true. Consequently, a low hypoglycemia knowledge score was directly affected by ITDM patients' hypoglycemia experience. Therefore, our main finding was that the knowledge score of ITDM patients was 15% higher among patients who experienced hypoglycemia than among those who did not. A low hypoglycemia knowledge score (≤ 6) was more common among ITDM patients who did not experience hypoglycemia than among those who did. This suggests that experiencing hypoglycemia as an outcome motivated ITDM patients to educate themselves about hypoglycemia, thereafter presumably engaging in better self-care to avoid future hyperglycemic episodes. This finding also highlights the importance of knowledge in reducing the risks associated with diabetes among ITDM patients. Similar observations have been reported wherein hypoglycemia knowledge was found to be critical to diabetic patients' self-care.¹⁹ Such observations require further research that specifically defines both the factors affecting poor knowledge of hypoglycemic symptoms among ITDM patients and how diabetic knowledge—both of broad and specific knowledge about hypoglycemia outcomes—affects the development of adverse effects.

Several conclusions can be drawn from this study that can help inform clinical practice. First, the majority of the participants with ITDM did experience sweating during hypoglycemic episodes; this can be used to develop an early warning sign system for the patient that may help lower the risk of developing hypoglycemia. Additionally, healthcare providers should encourage ITDM patients to participate in regular follow-up to monitor blood sugar levels, given that differences in insulin treatment parameters can yield differential effects on the development of hypoglycemia. Second, most of the participants with

ITDM who did not experience hypoglycemia had a low hypoglycemia knowledge score. Educating these patients about diabetes is an important intervention for reducing hypoglycemia events among them.²⁹ In addition, knowledge about hypoglycemia may produce more normal physiologic insulin profiles, with an associated lower risk of hypoglycemia.³⁰

This study had some limitations. Due to the study's design, data were collected via questionnaire; therefore, the quality of the data collected may have been affected by a recall bias. In addition, because the study targeted individuals with ITDM, the results may not be generalizable to evaluating the risk of experiencing hypoglycemia among other DM patients who are not receiving insulin treatments. Nevertheless, the strengths of our study included its large sample size and the novelty of the researched topic in Saudi Arabia.

Conclusions

This study identifies a connection between hypoglycemia and a multitude of variables in ITDM patients. The major issue exposing ITDM patients at risk of hypoglycemia was a lack of understanding about hypoglycemia. Although the knowledge score was greater in hypoglycemic individuals, it was comparatively low in people who did not develop hypoglycemia. Type 2 diabetics had a greater rate of hypoglycemia. The insulin treatment itself appears to directly affect the development of hypoglycemia in ITDM patients, with a number of factors playing contributing roles, such as the duration of treatment, the type of insulin, and the total number of total daily units. Finally, sweating was the most common clinical manifestation among hypoglycemic individuals, which could improve ITDM patients' quality of life if employed as an early warning indication of hypoglycemia.

Abbreviations

ITDM, type 1 diabetes mellitus; ESRD, end-stage renal disease; DKA, diabetic ketoacidosis; HHS, hyperglycemic hyperosmolar state; DAD, diabetes and driving.

Data Sharing Statement

The data analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics Statement

This study was approved by the Institutional Review Board (IRB) of the College of Medicine at King Saud

University (Ref. No. 16/0227/IRB). Additionally, the study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

Funding

This project was supported by the College of Medicine Research Centre, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.

Disclosure

The author reports no conflicts of interest for this work.

References

- Khan IA, Movva S, Shaik NA, et al. Investigation of calpain 10 (rs2975760) gene polymorphism in Asian Indians with gestational diabetes mellitus. *Meta Gene*. 2014;2:299–306. doi:10.1016/j.mgene.2014.03.001
- Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. *Ann Saudi Med*. 2011;31(1):19–23. doi:10.4103/0256-4947.75773
- Federation ID. International diabetes federation: IDF diabetes atlas. Brussels, Belgium; 2019. Available from: <https://www.diabetesatlas.org>. Accessed August 25, 2021.
- Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. *Diabetes Res Clin Pract*. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
- Alharbi KK, Abudawood M, Khan IA. Amino-acid amendment of arginine-325-tryptophan in rs13266634 genetic polymorphism studies of the SLC30A8 gene with type 2 diabetes-mellitus patients featuring a positive family history in the Saudi population. *J King Saud Univ Sci*. 2021;33(1):101258. doi:10.1016/j.jksus.2020.101258
- Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. *Curr Cardiol Rep*. 2019;21(4):1–8. doi:10.1007/s11886-019-1107-y
- Liew G, Wong VW, Ho IV. Mini review: changes in the incidence of and progression to proliferative and sight-threatening diabetic retinopathy over the last 30 years. *Ophthalmic Epidemiol*. 2017;24(2):73–80. doi:10.1080/09286586.2016.1259638
- Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. *Diabetologia*. 2019;62(1):3–16. doi:10.1007/s00125-018-4711-2
- Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas. *Diabetes Res Clin Pract*. 2020;162:108086. doi:10.1016/j.diabres.2020.108086
- Hanumanthaiah RG, Krishnappa PPB, Prasad D, Farahat S, Ranganath T. Acute metabolic complications of diabetes mellitus in a tertiary care center. *Int J Adv Med*. 2017;4(4):985. doi:10.18203/2349-3933.ijam20173071
- Cryer PE. Hypoglycemia in type 1 diabetes mellitus. *Endocrinol Metab Clin North Am*. 2010;39(3):641–654. doi:10.1016/j.ecl.2010.05.003
- Zimmerman C. *Iatrogenic Complications of Diabetes Mellitus: An Examination of Hospital-Acquired Diabetic Ketoacidosis and Severe Outpatient Hypoglycemia*[Thesis]. Yale Medicine Thesis Digital Library; 2019:3546. Available from: <https://elischolar.library.yale.edu/cgi/viewcontent.cgi?article=3546&context=ytmtdl>.
- Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. *Endocr Pract*. 2008;14(6):750–756. doi:10.4158/EP.14.6.750
- Freeland B. Hypoglycemia in diabetes mellitus. *Home Healthc Now*. 2017;35(8):414–419. doi:10.1097/NHH.0000000000000584
- Al-Agha AE, Alafif M, Abd-Elhameed IA. Glycemic control, complications, and associated autoimmune diseases in children and adolescents with type 1 diabetes in Jeddah, Saudi Arabia. *Saudi Med J*. 2015;36(1):26. doi:10.15537/smj.2015.1.9829
- Ahmed B, Khan MN. Hypoglycemia: its effect on patients with diabetes. *World Fam Med*. 2019;17(9):18–23. doi:10.5742/MEWFM.2019.93675
- AlKhalidi YM, AlKhalidi AY, AlQahtani AS, Al-Shahrani BS, Meshawi EA, Albishri BM. Incidence of hypoglycemia and its risk factors among diabetics during Ramadan in Abha city, Aseer Region, KSA. *J Fam Med Prim Care*. 2019;8(9):2793. doi:10.4103/jfmpc.jfmpc_250_19
- Elvebakk O, Tronstad C, Birkeland KI, et al. Evaluation of hypoglycaemia with non-invasive sensors in people with type 1 diabetes and impaired awareness of hypoglycaemia. *Sci Rep*. 2018;8(1):1–11. doi:10.1038/s41598-018-33189-1
- Drass JA, Feldman RH. Knowledge about hypoglycemia in young women with type I diabetes and their supportive others. *Diabetes Educ*. 1996;22(1):34–38. doi:10.1177/014572179602200105
- Shriram V, Mahadevan S, Anitharani M, et al. Knowledge of hypoglycemia and its associated factors among type 2 diabetes mellitus patients in a Tertiary Care Hospital in South India. *Indian J Endocrinol Metab*. 2015;19(3):378. doi:10.4103/2230-8210.152779
- Bhutani G, Kalra S, Lamba S, Verma PK, Saini R, Grewal M. Effect of diabetic education on the knowledge, attitude and practices of diabetic patients towards prevention of hypoglycemia. *Indian J Endocrinol Metab*. 2015;19(3):383. doi:10.4103/2230-8210.152781
- Elzubier AG. Knowledge of hypoglycemia by primary health care centers registered diabetic patients. *Saudi Med J*. 2001;22(3):219–222.
- Almigbal TH, Alfaifi AA, Aleid MA, et al. Safe driving practices and factors associated with motor-vehicle collisions among people with insulin-treated diabetes mellitus: results from the Diabetes and Driving (DAD) Study. *J Safety Res*. 2018;65:83–88. doi:10.1016/j.jsr.2018.03.003
- Corp I. *IBM SPSS Statistics for Windows, Version 22.0*. Armonk, NY: IBM Corp; 2013.
- Khan IA, Jahan P, Hasan Q, Rao P. Genetic confirmation of T2DM meta-analysis variants studied in gestational diabetes mellitus in an Indian population. *Diabetes Metab Syndr*. 2019;13(1):688–694. doi:10.1016/j.dsx.2018.11.035
- Tomky D. Detection, prevention, and treatment of hypoglycemia in the hospital. *Diabetes Spectr*. 2005;18(1):39–44. doi:10.2337/diaspect.18.1.39
- Madani AM, Mahmoud AN, Abdelrahim HM, El-Hadiyah TM, Yousif AK. Assessing knowledge of hypoglycemia symptoms among type 2 diabetic patients using insulin, Khartoum, Sudan. *Pharmacol Pharm*. 2019;10(1):21. doi:10.4236/pp.2019.101003
- Dailey G, Gao L, Aurand L, Garg S. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. *Diabetes Obes Metab*. 2013;15(12):1085–1092. doi:10.1111/dom.12131
- LaManna J, Litchman ML, Dickinson JK, et al. Diabetes education impact on hypoglycemia outcomes: a systematic review of evidence and gaps in the literature. *Diabetes Educ*. 2019;45(4):349–369. doi:10.1177/0145721719855931
- Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. *J Diabetes Complications*. 2004;18(1):60–68. doi:10.1016/S1056-8727(03)00058-8

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>